Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 4/20 | 0.71 |
| ▸ | RAB9A | P51151 | 3/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3563360 | 0.81 | KMT2A (0.80) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL2986728 | 0.76 | SMN1; SMN2 (1.00) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13241786 | 0.75 | SMN1; SMN2 (0.77) | KMT2AMEN1L3MBTL1SMN1; SMN2RECQL | |
| SCHEMBL7366160 | 0.73 | NPC1 (0.70) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL27712494 | 0.73 | NPC1 (0.67) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL13241784 | 0.72 | SMN1; SMN2 (0.62) | KMT2AMEN1SMN1; SMN2RECQLALDH1A1 | |
| SCHEMBL13997865 | 0.70 | KMT2A (0.77) | KMT2AMEN1NPC1SMN1; SMN2RECQL | |
| SCHEMBL10154240 | 0.70 | CA12 (0.77) | KMT2AMEN1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13997866 | 0.70 | SMN1; SMN2 (0.70) | KMT2AMEN1SMN1; SMN2RECQLALDH1A1 | |
| SCHEMBL13241810 | 0.70 | SMN1; SMN2 (0.73) | KMT2AMEN1SMN1; SMN2RECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250233-A1 | ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160250233-A1 | ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160250233-A1 | ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-9353051-B2 | Antiviral drugs for treatment or prevention of dengue infection | SIGA TECHNOLOGIES, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353051-B2 | Antiviral drugs for treatment or prevention of dengue infection | SIGA TECHNOLOGIES, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353051-B2 | Antiviral drugs for treatment or prevention of dengue infection | SIGA TECHNOLOGIES, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20130303491-A1 | Antiviral Drugs for Treatement or Prevention of Dengue Infection | SIGA TECHNOLOGIES INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303491-A1 | Antiviral Drugs for Treatement or Prevention of Dengue Infection | SIGA TECHNOLOGIES INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303491-A1 | Antiviral Drugs for Treatement or Prevention of Dengue Infection | SIGA TECHNOLOGIES INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-8518960-B2 | Antiviral drugs for treatment or prevention of dengue infection | SIGA TECHNOLOGIES, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518960-B2 | Antiviral drugs for treatment or prevention of dengue infection | SIGA TECHNOLOGIES, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518960-B2 | Antiviral drugs for treatment or prevention of dengue infection | SIGA TECHNOLOGIES, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20100189685-A1 | Antiviral Drugs for Treatment or Prevention of Dengue Infection | SIGA TECHNOLOGIES, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100189685-A1 | Antiviral Drugs for Treatment or Prevention of Dengue Infection | SIGA TECHNOLOGIES, INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2008147962-A1 | ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303491-A1 | Antiviral Drugs for Treatement or Prevention of Dengue Infection | HAVCR2, EIF2AK2, ZC3HAV1 | KMT2A 3936/4885MEN1 2863/4885NPC1 497/4885 |
| US-20100189685-A1 | Antiviral Drugs for Treatment or Prevention of Dengue Infection | EIF2AK2, HAVCR2, SNRPE | KMT2A 3347/4885MEN1 3401/4885NPC1 491/4885 |
| US-20160250233-A1 | ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION | EIF2AK2, HAVCR2, SNRPE | KMT2A 3347/4885MEN1 3401/4885NPC1 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.